Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mRNA
Biotech
BioNTech buys German mRNA vaccine peer CureVac in $1.2B deal
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.
James Waldron
Jun 12, 2025 8:17am
OSE to lead mRNA project with €1.3M from French government
May 21, 2025 4:26pm
Arcturus doubles down on mRNA, axes several early-stage assets
May 13, 2025 1:32pm
NewLimit raises $130M to push liver mRNA med into clinic
May 6, 2025 11:00am
Ex-FDA leader joins new initiative aiming to protect vaccine use
Apr 24, 2025 1:18pm
NIH allegedly cancels grants for vaccine hesitancy research
Mar 13, 2025 11:49am
